FDA Ends Emergency Use for Three Old COVID Tests
Published Date: 6/26/2026
Notice
Summary
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
BD Veritor EUA Revoked Feb 24, 2026
FDA revoked the Emergency Use Authorization (EUA) for the BD Veritor System for Rapid Detection of SARS-CoV-2 effective February 24, 2026. BD requested the revocation, told FDA there are no viable BD Veritor reagents remaining in U.S. distribution, and has transitioned to a cleared BD Veritor product under K243872; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
InBios SCoV-2 Detect EUA Revoked Feb 24, 2026
FDA revoked the Emergency Use Authorization (EUA) for InBios International, Inc.'s SCoV-2 Detect Neutralizing Ab ELISA effective February 24, 2026. InBios requested the revocation and stated there are no viable SCoV-2 Detect Neutralizing Ab ELISA reagents remaining in U.S. distribution; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
Roche Elecsys EUA Revoked March 2, 2026
FDA revoked the Emergency Use Authorization (EUA) for Roche Diagnostics' Elecsys Anti-SARS-CoV-2 effective March 2, 2026. Roche requested the revocation, indicated there are no viable Elecsys reagents remaining in U.S. distribution, and has transitioned to a cleared Elecsys product under K250768; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12933 — Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
2026-12900 — Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
2026-12899 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.
2026-12953 — Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RECTIV (nitroglycerin) ointment, 0.4%, wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules, so patients and pharmacies won’t face shortages or price spikes. If you’re a drug maker or user, this is good news for steady access and affordable options.
Previous / Next Documents
Previous: 2026-12893 — Combined Notice of Filings #1
Big energy players like Southwestern Electric Power and Appalachian Power are making moves to take over wind energy projects, which could shake up how electricity is generated and managed. The Federal Energy Regulatory Commission is reviewing these changes and some rate updates that might affect costs starting June 1, 2026. If you want to weigh in, comments are due by July 13, 2026, so don’t miss your chance!
Next: 2026-12907 — Evaluation of the California Coastal Management Program; Notice of Public Meetings; Request for Comments
NOAA is checking in on California’s Coastal Management Program and wants your thoughts! They’re hosting one in-person meeting and two online meetings in August 2026 to hear from folks about spaceports, oil, pipelines, desalination, and undersea cables. If you care about California’s coast, now’s the time to speak up before the August 22 deadline—no money changes yet, just your chance to shape the future!